eISSN: 1896-9151
ISSN: 1734-1922
Archives of Medical Science
Current issue Archive Special issues Abstracting and indexing Subscription
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications
2/2010
vol. 6
 
Share:
Send email
Share:
abstract:

Original research
Treatment with double dose of omeprazole increases -endorphin plasma level in patients with coronary artery disease

Jacek Budzyński
,
Grzegorz Pulkowski
,
Maria Kłopocka
,
Beata Augustyńska
,
Anna Sinkiewicz
,
Karol Suppan
,
Jacek Fabisiak
,
Marcin Majer
,
Maciej Świątkowski

Arch Med Sci 2010; 6, 2: 201-207
DOI: https://doi.org/10.5114/aoms.2010.13896
Online publish date: 2010/04/30
View full text Get citation
 
Introduction: The proton pump inhibitor empirical trial, besides the analysis of symptoms, is the main method in the diagnosis of gastro-oesophageal reflux disease-related chest pain. β-Endorphin acts as an endogenous analgesia system. The aim of the study was verify whether β-endorphin plasma level is affected by omeprazole administration and influences the severity of anginal symptoms and outcome of the “omeprazole test” in patients with coronary artery disease (CAD) and chest pain of suspected non-cardiac origin.
Material and methods: Omeprazole was administered to 48 patients with CAD in a randomized, placebo-controlled, crossover study design. At the beginning of the study, and again after the 14-day omeprazole and placebo treatment, the β-endorphin plasma concentration was determined.
Results: The level of plasma β-endorphin after the administration of omeprazole was significantly greater than at the start of the study and following the placebo. Responders to omeprazole had an average lower β-endorphin plasma concentration than subjects who failed to respond to this therapy. Subjects with symptoms in class III (according to the Canadian Cardiovascular Society classification) after omeprazole administration had a greater β-endorphin plasma level than subjects in class II for anginal symptom severity.
Conclusions: Fourteen-day therapy with a double omeprazole dose significantly increases the β-endorphin plasma concentration in patients with CAD. Circulating β-endorphin does not seem to be involved in the mechanism for the “omeprazole test” outcome, although an individually different effect on pain threshold cannot be excluded.
keywords:

β-endorphin, omeprazole test, chest pain, coronary artery disease
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2024 Termedia Sp. z o.o.
Developed by Bentus.